Ginkgo Bioworks DNA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -210.7%-18.7pp | -192%+7.5pp | -199.5%-61.1pp | -138.3%+65.2pp | -203.5%+43.0pp | |
| Net margin | -215.4%-20.0pp | -195.4%+3.7pp | -199.1%-56.3pp | -142.8%+64.9pp | -207.7%+33.3pp | |
| EBITDA margin | -170.3%-15.2pp | -155.1%+8.6pp | -163.7%-54.4pp | -109.3%+65.6pp | -175%+43.8pp | |
| Free cash flow margin | -119%-7.4pp | -111.7%-1.9pp | -109.8%+14.4pp | -124.2%+27.7pp | -151.9%+16.4pp | |
| Returns | ||||||
| Return on equity | -55.8%-4.7pp | -51.1%-1.1pp | -50%-6.4pp | -43.6%+14.2pp | -57.8%+2.6pp | |
| Return on assets | -26.2%-1.1pp | -25%+0.4pp | -25.4%-3.4pp | -22.1%+10.8pp | -32.8%+3.1pp | |
| Return on invested capital | -42.8%+4.0pp | -46.8%+1.6pp | -48.3%+8.7pp | -57%+30.2pp | -87.2%+33.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.2×+0.2× | 4.9×+0.5× | 4.4×-1.0× | 5.4×+0.5× | 4.9×-0.7× | |
| Quick ratio | 5.2×+0.2× | 4.9×+0.5× | 4.4×-1.0× | 5.4×+0.5× | 4.9×-0.7× | |
| Cash ratio | 2.4×+0.2× | 2.2×+0.9× | 1.4×-1.2× | 2.6×-0.5× | 3.1×-2.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.9×+0.1× | 0.9×+0.1× | 0.8×+0.1× | 0.7×0.0× | 0.7×0.0× | |
| Debt-to-assets | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Valuation | ||||||
| Market capitalization | $625.16M+24.6% | $503.5M-41.7% | $863.13M+60.5% | $537.91M+62.6% | $330.79M-41.4% | |
| Enterprise value | $847.19M+45.9% | $731.02M-35.3% | $1.13B+57.8% | $715.38M+74.5% | $409.95M-3.9% | |
| Price / sales | 4.4×+2.2× | 3.1×-1.9× | 5.1×+2.6× | 2.4×+1.0× | 1.5×-1.0× | |
| Price / book | 1.4×+0.6× | 1×-0.6× | 1.5×+0.7× | 0.9×+0.4× | 0.5×-0.3× | |
| EV / sales | 6×+3.4× | 4.6×-2.1× | 6.6×+3.4× | 3.2×+1.4× | 1.8×-0.1× | |
| Free cash flow yield | -26.9%+41.9pp | -35.5%-13.8pp | -21.7%+29.3pp | -51%+53.4pp | -104.4%-36.7pp | |
| Earnings yield | -48.7%+45.4pp | -62.1%-22.8pp | -39.3%+19.3pp | -58.6%+84.1pp | -142.7%-45.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Ginkgo Bioworks's ratios come from?
- Every ratio is computed from Ginkgo Bioworks's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
